In a report released today, Robyn Karnauskas from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $54.36.
Karnauskas covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Pfizer. According to TipRanks, Karnauskas has an average return of 7.4% and a 49.14% success rate on recommended stocks.
Currently, the analyst consensus on Bristol-Myers Squibb is a Hold with an average price target of $54.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Bristol-Myers Squibb’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $11.48 billion and a net profit of $1.76 billion. In comparison, last year the company earned a revenue of $11.41 billion and had a net profit of $2.02 billion
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb (BMY) Company Description:
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY:
- Bristol-Myers Squibb (NYSE:BMY) Shrugs off Analyst Cut
- Bristol Myers reports FDA approves Opdivo for first-line metastatic UC treatment
- Healthcare Stocks Retreat after New Task Force Is Formed
- 2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4
- Bristol Myers’ ozanimod shows efficacy and safety in multiple sclerosis trial
